Crinetics Pharmaceuticals Inc. (CRNX) is scheduled to make a presentation related to its drug candidate Atumelnant at the Endocrine Society's annual meeting on June 3, 2024.
Atumelnant, an oral, selective ACTH antagonist, is in development for the treatment of ACTH-dependent Cushing's syndrome and congenital adrenal hyperplasia (CAH).
During the upcoming meeting on June 3, the company will be presenting initial results from the ongoing phase II studies of Atumelnant in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.